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Qualitative  polymerase  chain  reaction  versus
quantitative polymerase  chain  reaction  for the
detection of  minimal  residual  disease  in children
with acute  lymphoblastic  leukemiaCarlos Alberto Scrideli ∗, Luiz Gonzaga Tone
heteroduplex analysis has proved to be a rapid and much
simpler and cheaper method than the use of clone-speciﬁcUniversidade de São Paulo (USP), Ribeirão Preto, SP, Brazil
In acute lymphoblastic leukemia (ALL), remission is classi-
cally deﬁned as the reestablishment of normal hematopoiesis
and the presence of less than 5% of the nucleated blast cell
population found by conventional microscopy; this is used
in older protocols to assess treatment response. Morpholog-
ical analysis, although useful and applicable at any center,
has proven to be of limited sensitivity, subjective and impre-
cise to study early response to treatment and this technique
does not appear to be sufﬁcient to identify patients at true
risk of relapse who  might beneﬁt from the intensiﬁcation of
treatment.1,2 For this reason, cytomorphological analysis has
been replaced by minimal residual disease (MRD) monitoring
in several treatment protocols and new deﬁnitions of remis-
sion and relapse in childhood ALL have been proposed.3
The analysis of MRD  has proved to be the strongest inde-
pendent prognostic factor in all studies analyzing large series
of patients with B-lineage and T-cell ALL, and speciﬁc molec-
ular subgroups such as patients with the BCR-ABL fusion gene
and ALL patients with MLL  gene rearrangements. This analy-
sis allows more  accurate risk group assignment and tailoring
the intensity of treatment, permitting reduction or intensiﬁ-
cation at the different treatment time points according to the
MRD level.4–9 MRD  monitoring can also guide treatment deci-
sions in relapsed patients and those who are candidates for
bone marrow transplantation.4,5,10,11
DOI of original article: http://dx.doi.org/10.1016/j.bjhh.2015.08.003.
 See paper by Paula et al. on pages 373–80.
∗ Corresponding author at: Departamento de Puericultura e Pediatria, Fa
(USP),  Avenida Bandeirantes, 3900, 14049-900 Ribeirão Preto, SP, Brazil.
E-mail address: scrideli@fmrp.usp.br (C.A. Scrideli).
http://dx.doi.org/10.1016/j.bjhh.2015.08.010
1516-8484/© 2015 Associac¸ão Brasileira de Hematologia, Hemoterapia
reserved.Sequential monitoring of MRD using more  sensitive and
speciﬁc techniques, such as quantitative real-time poly-
merase chain reaction (RQ-PCR) for immunoglobulin (Ig) and
T-cell receptor (TCR) gene rearrangements and ﬂow cytometry
analysis, with a detection power of one blast cell in 104–106
normal cells, has substantially reﬁned the assessment of
early response to treatment. Unfortunately these methods
are not only expensive, but technically complex and require
considerable technology and highly-specialized laboratories
to be routinely used in risk stratiﬁcation protocols for ALL;
they are therefore inaccessible to most treatment centers,
especially in developing countries.4,12 The development
of simpliﬁed MRD technologies is essential to allow the
potential beneﬁts of MRD monitoring to be extended to all
children with leukemia including those treated in low-budget
countries. Table 1 shows some characteristics of the main
methodologies used to detect MRD in ALL.
A clinically useful simpliﬁed MRD technique should be
economically viable, widely applicable, speciﬁc and sensitive
enough to predict the course of the disease. The detection
of clonal Ig and TCR rearrangements by PCR and homo-culdade de Medicina de Ribeirão Preto, Universidade de São Paulo
probes or ﬂow cytometry. In a multicenter retrospective
study, this was the strongest independent prognostic factor
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Table 1 – Characteristics of the methodologies used for minimal residual disease detection in acute lymphoblastic
leukemia (ALL)a.
Flow cytometry
immunophenotyping
RQ-PCR analysis of fusion
gene transcripts
RQ-PCR analysis of
Ig/TCR genes
Conventional PCR of
Ig/TCR genes and
homo/heteroduplex
analysis
Estimated
sensibility
3–4  colors: 10−3–10−4 10−4–10−6 10−4–10−5 10−2–10−3
6–8 colors: 10−4
Applicability B-ALL: >90% B-ALL: 25–40% B-ALL: 95% B-ALL: >90%
T-ALL: >90% T-ALL: 10–15% T-ALL: 90–95% T-ALL: >90%
Advantages Fast Relatively easy Applicable to the great
majority of B-ALL and
T-ALL cases
Cheaper
Information about the
whole sample cellularity
Sensitive Sensitive Relatively easy
Applicable to the great
majority of patients
Applicable to speciﬁc
leukemia subgroups
(BCR-ABL, MLL-AF4, etc.)
Well standardized Applicable to the great
majority of patients
Disadvantages Variable sensitivity due to
similarities between
normal regenerating cells
and leukemic cells
Limited standardization Expensive Not quantitative
Ideal at least two aberrant
immunophenotypes per
patient (chance of
immunophenotypic shifts)
Limited applicability in
ALL (absence of targets
in >50% of cases)
Requires extensive
experience and
knowledge
Low sensitivity–patients
with MRD levels
<10−2–10−3 are not
detected
Drug-induced modulation
of the immunophenotype
might inﬂuence the levels
of antigenic expression
Risk  of contamination Time consuming at
diagnosis: identiﬁcation
of the junctional regions
and sensitivity testing
Relatively expensive Differences in fusion
transcript expression
levels between the
patients
Need for (preferably)
two sensitive PCR
targets per patient
(≥10−4), because of the
chance of clonal
evolution
Limited standardization Stability of fusion gene
transcripts decreases
over time
PCR: polymerase chain reaction; RQ-PCR: quantitative real time polymerase chain reaction; Ig: immunoglobulin gene; TCR:  T-cell receptor gene;
B-ALL: B-lineage ALL; T-All: T-cell ALL.
i
m
1
c
i
h
s
w
1
i
d
a
p
m
s
m
ha Based on van Dongen et al.4, Schrappe et al.12 and Conter et al.13
n patients treated according to the Grupo Brasileiro de Trata-
ento da Leucemia Infantil-leucemia linfoide aguda protocol
999 (GBTLI-99).13 This method represents a good predictive
riterion of unfavorable course in children with ALL as it is able
n identify patients with a high risk of relapse. This method,
owever, was not truly quantitative and, due to its lower
ensitivity, it should be employed only to identify patients
ith a high residual tumor load.
Actually in the GBTLI-2009 protocols, MRD analysis at Days
4 and 35 of the induction phase has been used to strat-
fy patients as good and poor responders, guiding treatment
ecisions in all pediatric ALL subtypes.14 Due to the cost
nd technical complexity, MRD  analysis using patient speciﬁc
robes by RQ-PCR has been routinely used in very few treat-
ent centers in Brazil and no comparison of this method withimpliﬁed MRD  strategies to detect Ig or TCR clonal rearrange-
ents by conventional PCR and homo-heteroduplex analysis
as been published until now.In this issue of the Revista Brazileira de Hematology e
Hemoterapy, Paula et al.15 compared MRD monitoring using Ig
and TCR gene rearrangements by conventional PCR followed
by homo-heteroduplex analysis with clone-speciﬁc probes
to RQ-PCR at the end of induction in 44 children with ALL.
According to RQ-PCR MRD cut-off points established by the
GBTLI-2009 protocol, the agreement between the two methods
was 40% for B lineage ALL and 100% for T-cell ALL. MDR  detec-
tion by the simpliﬁed method was a signiﬁcant prognostic
factor for 3.5-year leukemia free survival. Surprising, the same
was not observed using the clone-speciﬁc RQ-PCR method.
Despite the deﬁciencies associated with the study design,
especially the relatively small number of patients analyzed,
the short follow up and the different protocols used – which
are well recognized by the authors – the results are interesting
and can be useful to aid the validation of alternative and cost
effective methods to detect MRD in centers with lower tech-
nological resources. Analysis of a larger series of patients with
oter.
r
1
1
1
1
1
1368  rev bras hematol hem
ALL using the same protocol is essential to deﬁne the real util-
ity of this simpliﬁed strategy in the treatment stratiﬁcation.
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